{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:50:34Z","timestamp":1792799434577,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70535-y","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T16:11:47Z","timestamp":1724515907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study"],"prefix":"10.1038","volume":"14","author":[{"given":"Vijayalakshmi Jawaharlal","family":"Nehru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jose Vandakunnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usharani","family":"Brammacharry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswari","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunavathy","family":"Pradhabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balasundaram Revathi","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azger Dusthackeer","family":"VN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthuraj","family":"Muthaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"70535_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jgar.2020.11.011","volume":"24","author":"N Singh","year":"2021","unstructured":"Singh, N., Singh, P. K., Singh, U., Garg, R. & Jain, A. Fluroquinolone drug resistance among MDR-TB patients increases the risk of unfavourable interim microbiological treatment outcome: An observational study. J. Glob. Antimicrob. Resist. 24, 40\u201344 (2021).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"70535_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijid.2014.03.1388","volume":"26","author":"J Ho","year":"2014","unstructured":"Ho, J., Jelfs, P. & Sintchenko, V. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis\u2014a surveillance study in New South Wales, Australia, and a review of global resistance rates. Int. J. Infect. Dis. 26, 149\u2013153 (2014).","journal-title":"Int. J. Infect. Dis."},{"key":"70535_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3904\/kjim.2019.045","volume":"34","author":"H-W Lee","year":"2019","unstructured":"Lee, H.-W. & Yim, J.-J. Fluoroquinolone resistance in multidrug-resistant tuberculosis patients. Korean J. Intern. Med. 34, 286\u2013287 (2019).","journal-title":"Korean J. Intern. Med."},{"key":"70535_CR4","first-page":"363","volume":"7","author":"R Sharma","year":"2019","unstructured":"Sharma, R., Singh, B. K., Kumar, P., Ramachandran, R. & Jorwal, P. Presence of Fluoroquinolone mono-resistance among drug-sensitive Mycobacterium tuberculosis isolates: An alarming trend and implications. CEGH 7, 363\u2013366 (2019).","journal-title":"CEGH"},{"key":"70535_CR5","unstructured":"Prasad, J., Kumar, P. & Ramachandran, R. Report of the First National Anti-Tuberculosis Drug Resistance Survey India: 2014\u20132016: Revised National TB Control Programme (2018). https:\/\/tbcindia.mohfw.gov.in."},{"key":"70535_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/jfmpc.jfmpc_576_21","volume":"11","author":"R Dutt","year":"2022","unstructured":"Dutt, R., Singh, R., Majhi, J. & Basu, G. Status of drug resistant tuberculosis among patients attending a tuberculosis unit of West Bengal: A record based cross-sectional study. J. Family Med. Prim. Care. 11, 84 (2022).","journal-title":"J. Family Med. Prim. Care."},{"key":"70535_CR7","doi-asserted-by":"publisher","first-page":"120440","DOI":"10.1016\/j.envpol.2022.120440","volume":"315","author":"S Bhatt","year":"2022","unstructured":"Bhatt, S. & Chatterjee, S. Fluoroquinolone antibiotics: Occurrence, mode of action, resistance, environmental detection, and remediation \u2013 A comprehensive review. Environ. Pollut. 315, 120440 (2022).","journal-title":"Environ. Pollut."},{"key":"70535_CR8","first-page":"101505","volume":"25","author":"A Kumar","year":"2024","unstructured":"Kumar, A., Harakuni, S., Paranjape, R., Korabu, A. S. & Prasad, J. B. Factors determining successful treatment outcome among notified tuberculosis patients in Belagavi district of North Karnataka. India. CEGH. 25, 101505 (2024).","journal-title":"India. CEGH."},{"key":"70535_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-1172-4","author":"S Kabir","year":"2020","unstructured":"Kabir, S. et al. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. BMC Pulm. Med. https:\/\/doi.org\/10.1186\/s12890-020-1172-4 (2020).","journal-title":"BMC Pulm. Med."},{"key":"70535_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/medicina59061005","volume":"59","author":"R Gopalaswamy","year":"2023","unstructured":"Gopalaswamy, R. et al. Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India. Medicina 59, 1005 (2023).","journal-title":"Medicina"},{"key":"70535_CR11","doi-asserted-by":"publisher","first-page":"e0261329","DOI":"10.1371\/journal.pone.0261329","volume":"16","author":"SMM Rahman","year":"2021","unstructured":"Rahman, S. M. M. et al. Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh. PLoS One 16, e0261329 (2021).","journal-title":"PLoS One"},{"key":"70535_CR12","unstructured":"Guidelines for Programmatic Management of Drug-resistant TB in India 2021, National TB Elimination Programme, Central TB Division, Ministry of Health and Family Welfare, Government of India, New Delhi, India. https:\/\/tbcindia.mohfw.gov.in."},{"key":"70535_CR13","unstructured":"MedCalc: MedCalc\u2019s Relative risk calculator. MedCalc Software Ltd, https:\/\/www.medcalc.org\/calc\/relative _ risk.php. (2024)."},{"key":"70535_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3904\/kjim.2018.052","volume":"34","author":"H Kim","year":"2019","unstructured":"Kim, H. et al. Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study. Korean J. Intern. Med. 34, 344\u2013352 (2019).","journal-title":"Korean J. Intern. Med."},{"key":"70535_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.2991\/jegh.k.191215.003","volume":"10","author":"S Sethi","year":"2020","unstructured":"Sethi, S. et al. Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay. J. Epidemiol. Glob. Health 10, 42 (2020).","journal-title":"J. Epidemiol. Glob. Health"},{"key":"70535_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2302837","author":"M Li","year":"2024","unstructured":"Li, M. et al. Transmission of Fluoroquinolones Resistance among Multidrug-Resistant Tuberculosis in Shanghai, China: A Retrospective population-based Genomic Epidemiology Study. Emerg Microb. Infect. https:\/\/doi.org\/10.1080\/22221751.2024.2302837 (2024).","journal-title":"Emerg Microb. Infect."},{"key":"70535_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/ijmr.IJMR_1220_17","volume":"149","author":"R Sharma","year":"2019","unstructured":"Sharma, R., Sharma, S. K., Singh, B. K., Mittal, A. & Kumar, P. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi India. Indian J. Med. Res. 149, 62\u201366 (2019).","journal-title":"Indian J. Med. Res."},{"key":"70535_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jgar.2017.08.014","volume":"12","author":"HG Mamatha","year":"2018","unstructured":"Mamatha, H. G. & Shanthi, V. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India. J. Glob. Antimicrob. Resist. 12, 5\u201310 (2018).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"70535_CR19","volume-title":"Global Tuberculosis Report 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Global Tuberculosis Report 2020 (WHO, 2020)."},{"key":"70535_CR20","doi-asserted-by":"publisher","DOI":"10.1590\/0074-02760200055","author":"T Matsui","year":"2020","unstructured":"Matsui, T. et al. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from S\u00e3o Paulo. Brazil. Mem Inst Oswaldo Cruz. https:\/\/doi.org\/10.1590\/0074-02760200055 (2020).","journal-title":"Brazil. Mem Inst Oswaldo Cruz."},{"key":"70535_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1356826","author":"MA Reta","year":"2024","unstructured":"Reta, M. A., Maningi, N. E. & Fourie, P. B. Patterns and profiles of drug resistance-conferring mutations in Mycobacterium tuberculosis genotypes isolated from tuberculosis-suspected attendees of spiritual holy water sites in Northwest Ethiopia. Front Public Health https:\/\/doi.org\/10.3389\/fpubh.2024.1356826 (2024).","journal-title":"Front Public Health"},{"key":"70535_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jor2010001","volume":"2","author":"M Aaina","year":"2021","unstructured":"Aaina, M. et al. Risk Factors and Treatment Outcome Analysis Associated with Second-Line Drug-Resistant Tuberculosis. J. Respir. 2, 1\u201312 (2021).","journal-title":"J. Respir."},{"key":"70535_CR23","first-page":"294","volume":"12","author":"R Dixit","year":"2023","unstructured":"Dixit, R. et al. Fluoroquinolone resistance mutations among Mycobacterium tuberculosis and their interconnection with treatment outcome. Int. J. Mycobacteriol. 12, 294\u2013298 (2023).","journal-title":"Int. J. Mycobacteriol."},{"key":"70535_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12941-021-00478-z","volume":"20","author":"M Ye","year":"2021","unstructured":"Ye, M. et al. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: A systematic review and meta-analysis. Ann. Clin. Microbiol. Antimicrob. 20, 73 (2021).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"70535_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/jac\/dkv360","volume":"71","author":"L Rigouts","year":"2015","unstructured":"Rigouts, L. et al. Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. J. Antimicrob. Chemother. 71, 314\u2013323 (2015).","journal-title":"J. Antimicrob. Chemother."},{"key":"70535_CR26","volume-title":"Global Tuberculosis Report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global Tuberculosis Report 2023 (WHO, 2023)."},{"key":"70535_CR27","doi-asserted-by":"publisher","first-page":"e0239328","DOI":"10.1371\/journal.pone.0239328","volume":"15","author":"S Tahseen","year":"2020","unstructured":"Tahseen, S. et al. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015\u201319. PLoS One 15, e0239328 (2020).","journal-title":"PLoS One"},{"key":"70535_CR28","first-page":"68","volume":"15","author":"K Suresh","year":"2021","unstructured":"Suresh, K., Vimala, Y., Mohan, N. & Padmaja, I. J. Additional Resistance to any Fluoroquinolones among Multidrug-resistant Mycobacterium tuberculosis Isolates from North Coastal Andhra Pradesh India. JPAM 15, 68\u201374 (2021).","journal-title":"JPAM"},{"key":"70535_CR29","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.2147\/IDR.S300814","volume":"14","author":"L Bogale","year":"2021","unstructured":"Bogale, L., Tsegaye, T., Abdulkadir, M. & Akalu, T. Y. Unfavorable Treatment Outcome and Its Predictors Among Patients with Multidrug-Resistance Tuberculosis in Southern Ethiopia in 2014 to 2019: A multi-center retrospective follow-up study. InfectDrug Resist. 14, 1343\u20131355 (2021).","journal-title":"InfectDrug Resist."},{"key":"70535_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5588\/pha.16.0055","volume":"7","author":"D Nair","year":"2017","unstructured":"Nair, D. et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. PHA 7, 32\u201338 (2017).","journal-title":"PHA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70535-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T16:13:17Z","timestamp":1724515997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70535"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70535-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4649926\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19719"}}